Integer Holdings Corporation

NYSE:ITGR

Medical - Devices

Healthcare
$126.97 +1.29%

+$1.16 today

Market cap
$4.32B
Beta
0.65
P/E (TTM)
21.9
EPS (TTM)
$4.14
52W Low $62.00High $123.78

Volume 0.80M

Average 0.54M

ITGR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Integer Holdings CorporationNYSE: ITGR

Research & Development · Q2 FY2026 · quarter ended Jul 2026

Research & development declines year over year

Q2 FY2026 research & development of $11.28M fell 20.8% year over year, behind the -4.7% change in trailing-twelve-month research & development. Sequentially, it fell 30.6% from the prior quarter. Over 3 fiscal years it compounded at -8.1% a year.

Context

  • Research & development amounted to 2.5% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.8% toward the trailing-twelve-month pace of -4.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
$11.28M-30.6% QoQ
Last fiscal yearDec 2025
$46.35M-13.2% YoY
LTMJul 2026
$48.58M-4.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.8%——
1 year-13.2%——
3-year CAGR-8.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
46.35M USD
Year-over-year change
-13.2%
4-year CAGR
-2.8%

Research & Development vs competitors

How ITGR compares with its peers on the latest reported figures

  • ITGR's LTM Jul 2026 research & development of $48.58M is the 6th highest of the 10 companies compared; the peer median is $59.46M.
  • Its year-over-year change of -4.7% is the 5th highest of 7, against a peer median of +3.5%.
  • Research & development amounts to 2.6% of revenue for ITGR, versus a peer median of 7.2%.
ITGR Competitors Peer median
Research & Development for ITGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$381.91M -11.4%+39.8%696.2%
LIVNLivaNova PLCLTM Sep 2026$202.57M +14.5%+6.0%13.4%
INSPInspire Medical Systems, Inc.LTM Jun 2026$99.68M -9.7%+14.5%11.1%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$73.13M +11.5%+35.0%22.7%
HAEHaemonetics CorporationLTM Jun 2026$59.46M -4.4%+0.6%4.4%
ITGRInteger Holdings CorporationLTM Jul 2026$48.58M -4.7%-8.1%2.6%
AORTArtivion, Inc.LTM Mar 2026$33.1M +17.2%-7.3%7.2%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$0 ——0.0%
UFPTUFP Technologies, Inc.LTM Jun 2026$0 ——0.0%
ADUSAddus HomeCare CorporationLTM Jun 2026$0 ——0.0%
Peer median (excluding ITGR) $59.46M+3.5%+10.3%7.2%

Competitors are the stored peer set for ITGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.22B1.33B1.56B1.72B1.85B
Cost of Revenue884.11M984.63M1.14B1.26B1.42B
Gross Profit336.97M346.65M411.52M461.18M425.81M
Gross Margin27.6%26.0%26.5%26.9%23.1%
Research & Development51.99M59.76M61.97M53.43M46.35M
Selling, General & Admin141.69M157.36M171.47M184.33M162.59M
Operating Expenses201.26M233.97M248.2M252.95M216.55M
Depreciation & Amortization81.37M91.99M98.84M111.03M130.67M
EBITDA224.43M222.84M277.56M334.27M298.38M
EBITDA Margin18.4%16.7%17.8%19.5%16.2%
Operating Income135.71M112.68M163.32M208.24M209.27M
Operating Margin11.1%8.5%10.5%12.1%11.3%
Interest Income00000
Interest Expense31.63M37.27M53.37M56.37M42.31M
Other Income / Expenses(34.65M)(44M)(57.94M)(60.68M)(83.87M)
Income Before Tax101.06M68.68M105.38M147.56M125.4M
Pre-Tax Margin8.3%5.2%6.8%8.6%6.8%
Income Tax Expense8.04M8.93M16.24M26.51M22.57M
Net Income96.81M66.38M90.65M119.9M102.76M
Net Margin7.9%5.0%5.8%7.0%5.6%
EPS (Basic)2.821.972.723.602.96
EPS (Diluted)2.801.962.693.402.89
Weighted Avg Shares32.99M33.13M33.32M33.6M34.74M
Weighted Avg Shares (Diluted)33.26M33.36M33.76M35.65M35.59M

Integer Holdings Corporation

NYSE:ITGR

Intrinsic Alpha fair value

Locked

Current Price

$126.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.